Saltigo signs agreement with Daiichi Sankyo
LANXESS subsidiary provides contract manufacturing services for major Japanese pharmaceutical company
Saltigo GmbH is continuing the development of its pharmaceutical business portfolio. The wholly owned LANXESS subsidiary signed in Tokyo an agreement with Daiichi Sankyo Co., Ltd. for the provision of contract manufacturing services. These are associated with the preparation for commercialization of one of Daiichi Sankyo’s novel drug pipeline projects. A corresponding signing ceremony took place in Tokyo.
Schmitz comments: “Daiichi Sankyo is one of the largest pharma players in the second largest pharma market in the world and decided to work with a globally recognized CMO-partner such as our company. So, it is a great honor for Saltigo to enter into this agreement with Daiichi Sankyo and we look forward to the continuation and further proactive development of our business relationship.”
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.